← Back to results

Posted · PAR-25-157

Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)

National Institutes of Health  ·  HHS

CFDA Numbers

93.350

Award Ceiling

Award Floor

Expected Awards

Close Date

Jun 18, 2026

Section I

How to Apply

Apply Online ↗

View on grants_gov ↗

Program Contact

NIH Grants Information <br/>grantsinfo@nih.gov
grantsinfo@nih.gov

Section II

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Eligible Applicant Types

00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25

Section III

Description

The National Center for Advancing Translational Sciences (NCATS) invites applications for the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) Notice of Funding Opportunity (NOFO) to foster investigator-initiated development of highly innovative technologies to address barriers, limitations, or bottlenecks in translational science particularly for therapeutic development. This program will support the early-stage proof of concept, high-risk and potentially high-reward studies for feasibility and exploratory technology development, which can transform or significantly improve the efficiency of therapeutic development to achieve NCATS ultimate goals - more treatments to all people more quickly. The research proposed should be for the development of technology that can break new ground or extend present technology toward new directions or novel applications. With this initiative, we expect to support the development and/or prototyping of new technologies that will lead to improved efficiency in the therapeutic development pipeline.

Section IV

Key Dates

Posted
Dec 10, 2024
Closes
Jun 18, 2026
Archive
Jul 18, 2026